NFKB1 and atherosclerosis: Experimental studies have fully exemplified that Danlou tablets can reduce myocardial ischemia and reperfusion injury (42), regulate procholesterol efflux, and perform anti-inflammation by activating the PPARα/ABCA1 signaling pathway; concurrently, the NF-κB signaling pathway is prevented, thereby playing its role in alleviating atherosclerosis (13).